Four facts you should know before taking Lorcaserin

1. Four facts you should know before taking Lorcaserin 1.How does the drug belviq work? How does Belviq work? The drug works by controlling appetite — specifically by activating brain receptors for serotonin, a neurotransmitter that triggers feelings of satiety and satisfaction. 2.How effective is it? According to clinical trial data submitted by Arena to the FDA, nearly half of dieters without Type 2 diabetes who used the medication lost at least 5% of their starting weight — or an average of 12 lbs. — over a year, compared with 23% of those taking a placebo. For best results, dieters are advised to use the medication together with a healthy diet and exercise program. The approved labeling for Belviq also recommends that people discontinue the drug if they fail to lose 5% of their body weight after 12 weeks; longer treatment is unlikely to lead to meaningful weight loss. 3. Who can use Lorcaserin? The FDA approved the medication for people who are obese (with a body mass index, or BMI, of 30 or higher) or who are overweight (with a BMI of 27 or above) and also have at least one weight-related health condition such as Type 2 diabetes, high blood pressure or high cholesterol.

2. 4.Are there any side effects? The most common side effects of Belviq in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth and constipation; in patients with diabetes, side effects include low blood sugar, headache, back pain, cough and fatigue. Reference 1. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (January 2008). "Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity". Journal of Medicinal Chemistry. 51 (2): 305–13. doi:10.1021/jm0709034. PMID 18095642. 2. "Lorcaserin New Drug Application". Drugs.com. 22 December 2009. Archived from the original on 3 March 2016. 3. Pollack A (16 September 2010). "F.D.A. Panel Rejects Diet Pill". The New York Times. Archived from the original on 17 July 2011. https://www.cmoapi.com/ https://www.cmoapi.com/our-products/lorcaserin/ https://www.facebook.com/Cmoapi-114510347044359/ https://www.pinterest.com/cmoapibiotech/boards/ https://sites.google.com/view/cmoapi-lorcaserin-for-sell/